Pre-surgical oncolytic virotherapy improves breast cancer outcomes

Abstract

Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).

Keywords

• oncolytic virotherapy
• neoadjuvant therapy
• breast cancer
• triple-negative breast cancer
• immune checkpoint blockade